EN DE
Watch Redsense Medical AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Redsense Medical AB (REDS) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Redsense Medical AB stock SEK 1.11, price SEK 3.58, that is 69.0% below the price, quality 40 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0006965158

RM Redsense Medical AB logo Thin data Nov 4, 2026

Redsense Medical AB

REDS · ST
Very expensive, weak quality

Our calculation puts a fair price 69% below what the stock costs today.

Low debt
Quality 40/100
Expensive Growth (revenue 5y +10.7 %/yr in SEK)
Mixed vs. peers (4/10)
Fair value kr 1.11 · Strongly overvalued
Loss-making · -2.5% net margin (TTM)
Negative free cash flow
Narrow moat 18/100
Thin data
Watch Redsense Medical AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 28.00 kr 2.54 Fair Value kr 1.11 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range kr 2.54 – kr 28.00 · fair‑value band kr 0.7300 – kr 1.39 · the kr 3.58 price screens above the kr 1.11 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Redsense Medical in your weekly email

Every Wednesday you see whether Redsense Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Redsense Medical AB (publ) provides an alarm in the event of blood leakage to monitor hemodialysis treatments in Europe, Canada, and Australia.

Show moreShow less

It offers alarm units, such as Redsense, an alarm system for monitoring the blood access during hemodialysis; sensor patches to monitor venous needle or catheter access; and Redsense clamps to automatically stop the blood flow. The company was founded in 2000 and is headquartered in Halmstad, Sweden.

Stock analysis

Redsense Medical AB (REDS) currently trades at kr 3.58, while our model-based Fair Value estimate is kr 1.11, 69% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: kr 0.7300 (bear) to kr 1.39 (bull), the price of kr 3.58 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Redsense Medical AB reported revenue of 24.0M SEK in FY2025 versus 9.4M SEK in FY2021, a compound +26.6%/yr. Reported net income was −7.2M SEK in FY2025.

Key figures

Market cap 58.9M SEK (≈ $6.0M) Micro · P/S ratio 2.13 · EPS (TTM) kr −0.2300 · Net margin −29.9% · Return on equity −1.8% · Return on assets (EBIT) −19.7% (5-year average) · Operating margin 4.3% · Revenue (TTM) 26.5M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).

What moves the price

The share trades about 26% below its 52-week high and 41% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −69%, REDS screens richer than that median.

Fair Value models

Bear kr 0.7300 Fair Value kr 1.11 Bull kr 1.39
Price kr 3.58 · Downside -69.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 0.7300 kr 1.11 kr 1.39 54
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.7300 kr 1.11 kr 1.39 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 23
How much profit the company makes from its sales and capital
Quality Growth 15
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 91
Debt, balance sheet and risk of trouble
Investment 54
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 40
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 31
Distance to the 52-week high, does not count
New shares 53
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−14.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−56.3% (2020) → −30.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

REDS screens overvalued: fair value 69% below the price. Compare with Abbott Laboratories, →

Compare Redsense Medical AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside −69.0% · Bottom 25%
Profitability
Return on assets −18.3% · Bottom 25%
Net margin (12 months) −2.5% · Below median
Operating margin (12 months) 4.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 13.0% · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.72× · Cheaper than median
P/S (12 months) 2.23× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)65 · sector 36
PAST (return on equity)0 · sector 17
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs REDS
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs REDS
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs REDS
DexCom, Inc DXCM $79.41 $87.35 +10% vs REDS
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs REDS
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs REDS
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs REDS
Abbott Laboratories, ABT $109.93 $75.28 −32% vs REDS
Medtronic plc MDT $101.80 $65.61 −36% vs REDS
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs REDS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Redsense Medical AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Redsense Medical AB Fair Value". https://www.fairvalue-calculator.com/stock/REDS

Frequently asked questions

Is Redsense Medical AB (REDS) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of kr 1.11 versus a price of kr 3.58, about 69% lower (overvalued).
What is the fair value of REDS?
Our model-based fair value for Redsense Medical AB is kr 1.11 (as of Nov 4, 2026), built from audited fundamentals. The current price: kr 3.58.
What is the quality score of REDS?
Redsense Medical AB has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Redsense Medical AB (REDS)?
Our model-based price target is the fair value of kr 1.11 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario kr 0.7300, optimistic scenario kr 1.39. It is a calculation from audited fundamentals, not an analyst target.
What is the Redsense Medical AB stock forecast for 2026?
Our models put fair value at kr 1.11, about 69% lower versus a price of kr 3.58 (overvalued). Cautious scenario kr 0.7300, optimistic scenario kr 1.39. The calculation is refreshed regularly with new filings.
What is the revenue of Redsense Medical AB (REDS)?
Redsense Medical AB reported trailing-twelve-month revenue of about 26.5M SEK (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Redsense Medical AB (REDS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Redsense Medical AB it is kr 1.11 per share (as of Nov 4, 2026), against a price of kr 3.58. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Redsense Medical AB stock overvalued or undervalued in 2026?
As of Nov 4, 2026, REDS trades above its calculated fair value: price kr 3.58, fair value kr 1.11, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of REDS?
No. The price is what the market pays today (kr 3.58); the fair value is what the company's own numbers justify (kr 1.11). For Redsense Medical AB the two are kr 2.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Redsense Medical AB worth?
The market values Redsense Medical AB at about 58.9M SEK (market capitalisation, as of Nov 4, 2026). Per share that is kr 3.58; our models calculate a fair value of kr 1.11 per share.
What do the bullish and bearish scenarios say about REDS?
Our models span a range for Redsense Medical AB: cautious scenario kr 0.7300, base kr 1.11, optimistic kr 1.39 per share (as of Nov 4, 2026, price kr 3.58). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Redsense Medical AB (REDS)?
Balance-sheet figures for Redsense Medical AB (as of Nov 4, 2026): return on equity −1.8%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is REDS from its 52-week high?
Redsense Medical AB trades at kr 3.58, about 26% below its 52-week high of kr 4.86 and 41% above the low of kr 2.54 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.11 is for.
Which stocks are comparable to Redsense Medical AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Redsense Medical AB stock attractive at the current price?
The data as of Nov 4, 2026: price kr 3.58, calculated fair value kr 1.11 (−69%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of REDS calculated?
We run Redsense Medical AB through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of kr 1.11 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Redsense Medical AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Redsense Medical AB (REDS)?
The closing price on Nov 6, 2026 was kr 3.58. Our model-based fair value is kr 1.11, about 69% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Redsense Medical AB right now?
The price sits above even our optimistic bull case (kr 1.39). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.7300 to kr 1.39) leaves room in how you read the outcome.

Key figures of Redsense Medical AB

How large is the market capitalisation of Redsense Medical AB (REDS)?
The market capitalisation of Redsense Medical AB is 58.9M SEK (≈ $6.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Redsense Medical AB (REDS)?
The price-to-sales ratio of Redsense Medical AB is 2.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Redsense Medical AB (REDS)?
Earnings per share at Redsense Medical AB are kr −0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Redsense Medical AB (REDS)?
The net margin of Redsense Medical AB is −29.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Redsense Medical AB (REDS)?
The return on equity (ROE) of Redsense Medical AB is −1.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Redsense Medical AB (REDS)?
On an EBIT basis the return on assets of Redsense Medical AB is −19.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Redsense Medical AB (REDS)?
The operating margin of Redsense Medical AB is 4.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Redsense Medical AB (REDS)?
Revenue at Redsense Medical AB is growing +13.0% versus a year earlier (3y avg +18.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Redsense Medical AB (REDS) generate?
The free cash flow of Redsense Medical AB is −8.0M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Redsense Medical AB in the live analysis

One click puts Redsense Medical AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.